Navigation Links
deCODE Genetics Announces Full-year 2007 Financial Results
Date:3/12/2008

REYKJAVIK, ICELAND, March 12 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter and year ended December 31, 2007. A conference call to discuss the year's results and operating highlights will be webcast live tomorrow, Thursday, March 13, at 8:00am EDT/12 noon GMT (details below).

Net loss for the year ended December 31, 2007 was $95.5 million, compared to $85.5 million for the full year 2006. Basic and diluted net loss per share was $1.57 for the full year 2007, compared to $1.49 for the full year 2006. At the close of 2007, the company had approximately 61.7 million shares outstanding.

Revenue for the year ended December 31, 2007 was $40.4 million, versus $40.5 million for the full year 2006. At December 31, 2007, the company had $15.4 million in deferred revenue, which will be recognized over future reporting periods.

Research and development expense for proprietary programs was $53.8 million for the full year 2007, compared to $57.1 million for the full year 2006. Selling, general and administrative expenses for the full year 2007 were $27.1 million, compared to $25.2 million for 2006.

At December 31, 2007, the company had $94.1 million in cash and cash equivalents, restricted cash equivalents and current and non-current investments, compared to $152.0 million at December 31, 2006. As discussed below, the year end 2007 figure includes temporary and other-than-temporary impairment charges resulting from an independent, third-party estimate of the current value of certain auction-rate securities (ARS) held by the company.

"Over the past year we have made steady progress in both our near-term and long-term strategy to capitalize on
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
2. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results
3. deCODE genetics Announces Third Quarter 2007 Financial Results
4. deCODE Launches deCODEme(TM)
5. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference
6. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
7. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. Digital Unions RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Presbycusis, or age-related hearing loss, accounts for 30 percent ... lose their hearing as they get older but other people ... answer may be in a study released online in the ... online at http://hmg.oxfordjournals.org/papbyrecent.dtl . "This ...
... find their way back to their birthplace to reproduce after ... scientists for more than a century. But marine biologists at ... might finally have unraveled the secret. At the beginning ... magnetic field of their home area and "imprint" on it, ...
... meaning of a rare mineral that can be used to track ... others better understand what we,re probably in for over the next ... heat and, ultimately, to change life as we know it. ... in the next hundred years or so, and that many species ...
Cached Biology News:House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss 2No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Foretelling a major meltdown 2Foretelling a major meltdown 3
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Biology Products: